Transcriptomics in Parkinson’s disease offers insights into the pathogenesis of Parkinson’s disease but obtaining brain tissue has limitations. In order to bypass this issue, we profile and compare differentially expressed genes and enriched pathways (KEGG) in two peripheral tissues (blood and skin) of 12 Parkinson’s disease patients and 12 healthy controls using RNA-sequencing technique and validation with RT-qPCR. Furthermore, we compare our results to previous Parkinson’s disease post mortem brain tissue and blood results using the robust rank aggregation method. The results show no overlapping differentially expressed genes or enriched pathways in blood vs. skin in our sample sets (25 vs. 1068 differentially expressed genes with an FDR ≤ 0.05; 1 vs. 9 pathways in blood and skin, respectively). A meta-analysis from previous transcriptomic sample sets using either microarrays or RNA-Seq yields a robust rank aggregation list of cortical gene expression changes with 43 differentially expressed genes; a list of substantia nigra changes with 2 differentially expressed genes and a list of blood changes with 1 differentially expressed gene being statistically significant at FDR ≤ 0.05. In cortex 1, KEGG pathway was enriched, four in substantia nigra and two in blood. None of the differentially expressed genes or pathways overlap between these tissues. When comparing our previously published skin transcription analysis, two differentially expressed genes between the cortex robust rank aggregation and skin overlap. In this study, for the first time a meta-analysis is applied on transcriptomic sample sets in Parkinson’s disease. Simultaneously, it explores the notion that Parkinson’s disease is not just a neuronal tissue disease by exploring peripheral tissues. The comparison of different Parkinson’s disease tissues yields surprisingly few significant differentially expressed genes and pathways, suggesting that divergent gene expression profiles in distinct cell lineages, metabolic and possibly iatrogenic effects create too much transcriptomic noise for detecting significant signal. On the other hand, there are signs that point towards Parkinson’s disease-specific changes in non-neuronal peripheral tissues in Parkinson’s disease, indicating that Parkinson’s disease might be a multisystem disorder.
VerstraetenATheunsJVan BroeckhovenC.Progress in unraveling the genetic etiology of parkinson disease in a genomic era. Trends Genet2015;
31:140–9
4.
Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R; International Parkinson's Disease Genomics Consortium (IPDGC); Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI); 23andMe; GenePD; NeuroGenetics Research Consortium (NGRC); Hussman Institute of Human Genomics (HIHG); Ashkenazi Jewish Dataset Investigator; Cohorts for Health and Aging Research in Genetic Epidemiology (CHARGE); North American Brain Expression Consortium (NABEC); United Kingdom Brain Expression Consortium (UKBEC); Greek Parkinson's Disease Consortium; Alzheimer Genetic Analysis Group, Ikram MA, Ioannidis JP, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB..Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet2014;
46:989–93
5.
HardyJ.Genetic analysis of pathways to Parkinson disease. Neuron2010;
68:201–6
6.
Kadastik-EermeLTabaNAsserTTabaP.Incidence and mortality of Parkinson’s disease in Estonia. Neuroepidemiology2019;
53:63–72
7.
SullivanPFFanCPerouCM.Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet2006;
141B:261–8
8.
Cooper-KnockJKirbyJFerraiuoloLHeathPRRattrayMShawPJ.Gene expression profiling in human neurodegenerative disease. Nat Rev Neurol2012;
8:518–30
9.
KauczynskaKMPraveenSToftJASkogarMSæbøOLönneborgetS.A. Found in transcription: accurate Parkinson's disease classification in peripheral blood. J Park Dis2013;
3:19–29
10.
Aguiar Pm deCSeverinoP.Biomarkers in Parkinson disease: global gene expression analysis in peripheral blood from patients with and without mutations in PARK2 and PARK8. Einstein São Paulo2010;
8:291–7
11.
ShehadehLAYuKWangLGuevaraASingerCVanceJ.SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson’s disease.PLoS One2010;
5:e9104
12.
AlievaAKShadrinaMIFilatovaEVKarabanovAVIllarioshkinSNLimborskaSASlominskyPA.Involvement of endocytosis and alternative splicing in the formation of the pathological process in the early stages of Parkinson’s disease. BioMed Res Int2014;
2014:1–6
13.
InfanteJPrietoCSierraMSánchez-JuanPGonzález-AramburuISánchez-QuintanaCBercianoJCombarrosOSainzJ.Identification of candidate genes for Parkinson’s disease through blood transcriptome analysis in LRRK2-G2019S carriers, idiopathic cases, and controls. Neurobiol Aging2015;
36:1105–9
14.
InfanteJPrietoCSierraMSánchez-JuanPGonzález-AramburuISánchez-QuintanaCBercianoJCombarrosOSainzJ.Comparative blood transcriptome analysis in idiopathic and LRRK2 G2019S-associated Parkinson’s disease. Neurobiol Aging2016;
38:214.e1–e5
15.
PinhoRGuedesLCSoreqLLoboPPMestreTCoelhoMRosaMMGonçalvesNWalesPMendesTGerhardtEFahlbuschCBonifatiVBoninMMiltenberger-MiltényiGBoroveckiFSoreqH.FerreiraJJOuteiroTF.Gene expression differences in peripheral blood of Parkinson’s disease patients with distinct progression profiles. PLoS One2016;
11:e0157852
PotashkinJASantiagoJARavinaBMWattsALeontovichAA.Biosignatures for Parkinson’s disease and atypical parkinsonian disorders patients.PLoS One2012;
7:e43595
18.
ScherzerCREklundACMorseLJLiaoZLocascioJJFeferDSchwarzschildMASchlossmacherMGHauserMAVanceJMSudarskyLRStandaertDGGrowdonJHJensenRVGullansSR.Molecular markers of early Parkinson’s disease based on gene expression in blood. Proc Natl Acad Sci U S A2007;
104:955–60
19.
FuRHLiuSPHuangSJChenHJChenPRLinYHHoJCChangWLTsaiCHShyuWCLinetSZ.Aberrant alternative splicing events in Parkinson’s disease. Cell Transplant2013;
22:653–61
20.
WangZGersteinMSnyderM.RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet2009;
10:57–63
21.
ZhaoSFung-LeungW-PBittnerANgoKLiuX.Comparison of RNA-Seq and microarray in transcriptome profiling of activated T cells.PLoS One2014;
9:e78644
22.
van ItersonM’t HoenPPedottiPHooiveldGJEJden DunnenJTvan OmmenGJBBoerJMMenezesRX.Relative power and sample size analysis on gene expression profiling data. BMC Genomics2009;
10:439
23.
GuoYZhaoSLiC-IShengQShyrY.RNAseqPS: a web tool for estimating sample size and power for RNAseq experiment. Cancer Inform2014;
13:1–5
24.
BorrageiroGHaylettWSeedatSKuivaniemiHBardienS.A review of genome-wide transcriptomics studies in Parkinson’s disease. Eur J Neurosci2018;
47:1–16
25.
KoldeRLaurSAdlerPViloJ.Robust rank aggregation for gene list integration and meta-analysis. Bioinformatics2012;
28:573–80
26.
PlankenAKurvitsLReimannEKadastik-EermeLKingoKKõksSTabaP.Looking beyond the brain to improve the pathogenic understanding of Parkinson’s disease: implications of whole transcriptome profiling of patients’ skin. BMC Neurol2017;
17:6
GoetzCGTilleyBCShaftmanSRStebbinsGTFahnSMartinez-MartinPPoeweWSampaioCSternMBDodelRDuboisBHollowayRJankovicJKulisevskyJLangAELeesALeurgansSLeWittPANyenhuisDOlanowCWRascolOSchragATeresiJAvan HiltenJJLaPelleN, Movement Disorder Society UPDRS Revision Task Force.
Movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord2008;
23:2129–70
29.
HoehnMMYahrMD.Parkinsonism: onset, progression and mortality. Neurology1967;
17:427–42
30.
SchwabRSEaigf, DonaldsonIML. Projection technique for evaluating surgery in Parkinson’s disease. In: ■ (eds) 3rd symposium on surgery in Parkinson’s disease. Edinburgh: Livingstone, 1969, pp.152–157.
31.
FolsteinMFFolsteinSEMcHughPR.Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975;
12:189–98
32.
LoveMIHuberWAndersS.Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol2014;
15:550
33.
YuGWangLGHanYHeQY.clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS J Integr Biol2012;
16:284–7
34.
Henderson-SmithACorneveauxJJDe BothMCuyuganLLiangWSHuentelmanMAdlerCDriver-DunckleyEBeachTGDunckleyTL.Next-generation profiling to identify the molecular etiology of parkinson dementia. Neurol Genet2016;
2:e75
35.
DumitriuAGoljiJLabadorfATGaoBBeachTGMyersRHLongoKALatourelleJC.Integrative analyses of proteomics and RNA transcriptomics implicate mitochondrial processes, protein folding pathways and GWAS loci in parkinson disease. BMC Med Genomics2015;
9:5
36.
StamperCSiegelALiangWSPearsonJWStephanDAShillHConnorDCavinessJNSabbaghMBeachTGAdlerCHDunckleyT.Neuronal gene expression correlates of Parkinson’s disease with dementia. Mov Disord2008;
23:1588–95
37.
BossersKMeerhoffGBalesarRvan DongenJWKruseCGSwaabDFVerhaagenJ.Analysis of gene expression in Parkinson’s disease: possible involvement of neurotrophic support and axon guidance in dopaminergic cell death. Brain Pathol2009;
19:91–107
38.
SimunovicFYiMWangYMaceyLBrownLTKrichevskyAMAndersenSLStephensRMBenesFMSonntagKC.Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson’s disease pathology. Brain2009;
132:1795–809
39.
Cantuti-CastelvetriIKeller-McGandyCBouzouBAsterisGClarkTWFroschMPStandaertDG.Effects of gender on nigral gene expression and parkinson disease. Neurobiol Dis2007;
26:606–14
40.
DijkstraAAIngrassiaAde MenezesRXvan KesterenRERozemullerAJMHeutinkPvan de BergWDJ.Evidence for immune response, axonal dysfunction and reduced endocytosis in the substantia nigra in early stage Parkinson’s disease.PLoS One2015;
10:e0128651.
41.
DurrenbergerPFGrünblattEFernandoFSMonoranuCMEvansJRiedererPReynoldsRDexterTD.Inflammatory pathways in Parkinson’s disease; a BNE microarray study. Park Dis2012;
2012:1–16
42.
SantiagoJAPotashkinJA.Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson’s disease. Proc Natl Acad Sci U S A2015;
112:2257–62
43.
KedmiMBar-ShiraAGurevichTGiladiNOrr-UrtregerA.Decreased expression of B cell related genes in leukocytes of women with Parkinson’s disease. Mol Neurodegener2011;
6:66
44.
SoreqLIsraelZBergmanHSoreqH.Advanced microarray analysis highlights modified neuro-immune signaling in nucleated blood cells from Parkinson’s disease patients. J Neuroimmunol2008;
201-202:227–36
45.
LiuYZhouJWhiteKP.RNA-seq differential expression studies: more sequence or more replication?Bioinformatics2014;
30:301–4
46.
ChingTHuangSGarmireLX.Power analysis and sample size estimation for RNA-Seq differential expression. RNA2014;
20:1684–96
47.
SchurchNJSchofieldPGierlińskiMColeCSherstnevASinghVWrobelNGharbiKSimpsonGGOwen-HughesTBlaxterMBarton1GJ.How many biological replicates are needed in an RNA-seq experiment and which differential expression tool should you use?RNA2016;
22:839–51
48.
RosenbergerJPetrovicsGBuzasB.Oxidative stress induces proorphanin FQ and proenkephalin gene expression in astrocytes through p38- and ERK-MAP kinases and NF-κB: oxidative stress and proorphanin FQ. J Neurochem2008;
79:35–44
49.
MolochnikovLRabeyJMDobronevskyEBonuccelliUCeravoloRFrosiniDGrünblattERiedererPJacobCAharon-PeretzJBashenkoYYoudimMBHMandelSA.A molecular signature in blood identifies early Parkinson’s disease. Mol Neurodegener2012;
7:26
50.
SmithSBDampierWTozerenABrownJRMagid-SlavM.Identification of common biological pathways and drug targets across multiple respiratory viruses based on human host gene expression analysis.PLoS One2012;
7:e33174
51.
KalchmanMAGrahamRKXiaGKoideHBHodgsonJGGrahamKCGoldbergYPGietzRDPickartCMHaydenMR.Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J Biol Chem1996;
271:19385–94
52.
VarmaVRVarmaSAnYHohmanTJSeddighiSCasanovaRBeriADammerEBSeyfriedNTPletnikovaOMoghekarAWilsonMRLahJJO'BrienRJLeveyAITroncosoJCAlbertMSThambisettyM.Alpha-2 macroglobulin in Alzheimer’s disease: a marker of neuronal injury through the RCAN1 pathway. Mol Psychiatry2017;
22:13–23
53.
JinUParkSJParkSM.Cholesterol metabolism in the brain and its association with Parkinson’s disease. Exp Neurobiol2019;
28:554–67
54.
HuangXSterlingNWDuGSunDStetterCKongLZhuYNeighborsJLewisMMChenHHohlRJMailmanRB.Brain cholesterol metabolism and Parkinson’s disease. Mov Disord2019;
34:386–95
55.
AlecuIBennettSAL.Dysregulated lipid metabolism and its role in α-Synucleinopathy in Parkinson’s.Disease Front Neurosci2019;
13:328
56.
WeydtPPinedaVVTorrenceAELibbyRTSatterfieldTFLazarowskiERGilbertMLMortonGJBammlerTKStrandADCuiLBeyerRPEasleyCNSmithACKraincDLuquetSSweetIRSchwartzMWLa SpadaAR.Thermoregulatory And metabolic defects in Huntington’s disease transgenic mice implicate PGC-1α in Huntington’s disease neurodegeneration. Cell Metab2006;
4:349–62
57.
SinghAKukretiRSasoLKukretiS.Oxidative stress: a key modulator in neurodegenerative diseases. Molecules2019;
24:1583
58.
EstradaLDAhumadaPCabreraDArabJP.Liver dysfunction as a novel player in alzheimer’s progression: looking outside the brain. Front Aging Neurosci2019;
11:174
59.
MartinHLMounseyRBMustafaSSatheKTeismannP.Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson’s disease. Exp Neurol2012;
235:528–38
60.
GiuffridaAMartinezA. The endocannabinoid system and parkinson disease. In: ■ (eds) The endocannabinoid system. Amsterdam: Elsevier, 2017, pp.63–81
61.
CastilloPEYountsTJChávezAEHashimotodaniY.Endocannabinoid signaling and synaptic function. Neuron2012;
76:70–81
62.
RíoCdel MillánEGarcíaVAppendinoGDeMesaJMuñozE.The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders. Biochem Pharmacol2018;
157:122–33
63.
LiuRGaoXLuYChenH.Meta-analysis of the relationship between parkinson disease and melanoma. Neurology2011;
76:2002–9
64.
KosloskiLMKosmacekEAOlsonKEMosleyRLGendelmanHE.GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice. J Neuroimmunol2013;
265:1–10
65.
GillettAThessen HedreulMKhademiMEspinosaABeyeenADJagodicMKockumIHarrisRAOlssonT.Interleukin 18 receptor 1 expression distinguishes patients with multiple sclerosis. Mult Scler J2010;
16:1056–65
66.
SchlachetzkiJCMProtsITaoJChunHBSaijoKGosselinDWinnerBGlassCKWinklerJ.A monocyte gene expression signature in the early clinical course of Parkinson’s disease. Sci Rep2018;
8:10757
67.
BrundinPMelkiR.Prying into the prion hypothesis for Parkinson’s disease. J Neurosci2017;
37:9808–18
McGeerPLMcGeerEG.Inflammation and neurodegeneration in Parkinson’s disease. Parkinsonism Relat Disord2004;
10:S3–S7
70.
XiangWChaoZYFengDY.Role of toll-like receptor/MYD88 signaling in neurodegenerative diseases. Rev Neurosci2015;
26:407–14.
71.
ZaichickSVMcGrathKMCaraveoG.The role of Ca 2+ signaling in Parkinson’s disease. Dis Model Mech2017;
10:519–35
72.
EspositoGAna ClaraFVerstrekenP.Synaptic vesicle trafficking and Parkinson’s disease. Dev Neurobiol2012;
72:134–44
73.
HeindryckxFLiJP.Role of proteoglycans in neuro-inflammation and Central nervous system fibrosis. Matrix Biol2018;
68-69:589–601
74.
LabadorfAChoiSHMyersRH.Evidence for a pan-neurodegenerative disease response in Huntington’s and Parkinson’s disease expression profiles. Front Mol Neurosci2018;
10:430
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
